Evaluation of serum soluble triggering receptor expressed on myeloid cells-1 in polycystic ovary syndrome
Abstract
Objective: This study aims to investigate the clinical significance of serum soluble triggering receptor expressed on myeloid cells-1 levels in patients with polycystic ovary syndrome.
Methods: This case-control study included 40 women with polycystic ovary syndrome and 40 healthy control women. Serum soluble triggering receptor expressed on myeloid cells-1 and high-sensitive C-reactive protein levels were measured via commercially available enzyme-linked immunosorbent assay, according to the manufacturer's instructions.
Results: Soluble triggering receptor expressed on myeloid cells-1 levels were statistically significantly higher in women with polycystic ovary syndrome than controls (p<0.001). In the logistic regression analysis, an increase in serum soluble triggering receptor expressed on myeloid cells-1 level demonstrated a significant association with polycystic ovary syndrome diagnosis (p=0.011). In the receiver operating characteristic curve analysis, the area under the curve (AUC) for soluble triggering receptor expressed on myeloid cells-1 was found to be 0.800 (p<0.001). Setting the cut-off value at 45.22 pg/mL, soluble triggering receptor expressed on myeloid cells-1 demonstrated a sensitivity of 87.5% and a specificity of 65.0%. In the logistic regression analysis that incorporated homeostatic model assessment for insulin resistance, anti-müllerian hormone, and soluble triggering receptor expressed on myeloid cells-1, a 1 pg/mL rise in soluble triggering…
How strong is the evidence?
Evidence Hub reads this as a case-control, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 40 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.